MESO
Mesoblast Limited NASDAQ Listed Jan 20, 2010$15.50
+7.86%
vs $14.37
Mkt Cap $1.9B
52w Low $10.16
49.4% of range
52w High $20.96
50d MA $14.96
200d MA $16.24
P/E (TTM)
-18.4x
EV/EBITDA
—
P/B
3.1x
Debt/Equity
0.2x
ROE
—
P/FCF
-36.9x
RSI (14)
56.10
ATR (14)
$0.49
Beta
0.82
50d MA
$14.96
200d MA
$16.24
Avg Volume
169.8K
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
55 Collins Street · Melbourne, VIC 3000 · AU
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | AMC | -0.24 | -0.31 | -31.2% | 16.92 | -6.6% | -6.3% | -8.5% | +0.3% | +0.2% | +7.5% | — |
| Sep 3, 2025 | AMC | -0.37 | -0.21 | +43.0% | 12.88 | +1.7% | +5.0% | +6.4% | +1.1% | +3.1% | +3.7% | — |
| Apr 30, 2025 | AMC | — | -0.21 | — | 11.40 | +4.2% | +4.7% | +0.9% | -6.2% | -3.7% | +1.6% | — |
| Feb 26, 2025 | AMC | -0.25 | -0.21 | +16.1% | 15.72 | +3.7% | -1.1% | +10.4% | -10.1% | -4.5% | +0.7% | — |
| Oct 30, 2024 | AMC | -0.31 | -0.28 | +9.7% | 8.81 | -3.5% | -4.9% | +1.2% | -1.7% | +5.2% | -0.5% | — |
| Jul 4, 2024 | AMC | -0.35 | -0.26 | +25.7% | — | — | — | — | — | — | — | — |
| Mar 25, 2024 | AMC | -0.40 | -0.34 | +15.0% | 2.20 | +28.2% | +78.6% | -11.2% | +43.6% | +21.4% | +8.4% | — |
| Dec 26, 2023 | AMC | -0.25 | -0.12 | +51.3% | 2.14 | -2.8% | +1.9% | -0.9% | +1.9% | -1.8% | -3.7% | — |
| Aug 30, 2023 | AMC | -0.28 | -0.28 | -1.1% | 2.86 | +11.2% | +12.6% | -7.5% | +0.7% | +0.0% | -0.7% | — |
| May 25, 2023 | AMC | -0.31 | -0.26 | +17.4% | 6.90 | +8.1% | +5.2% | -4.1% | -2.9% | +4.1% | +3.1% | — |
| Feb 27, 2023 | AMC | -0.27 | -0.34 | -28.1% | 6.40 | +3.4% | +3.1% | -2.1% | -1.9% | +0.3% | +1.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 25 | Jefferies | Upgrade | Hold → Buy | — | $15.62 | $16.19 | +3.6% | +2.8% | +8.2% | -0.8% | -1.3% | -2.5% |
| Jul 18 | Jefferies | Downgrade | Buy → Hold | — | $12.34 | $15.40 | +24.8% | +26.6% | -6.2% | +2.9% | +6.7% | +5.5% |
| Feb 7 | Piper Sandler | Maintains | Overweight → Overweight | — | $18.69 | $19.84 | +6.2% | +4.3% | -4.2% | -2.4% | +1.6% | -0.6% |
| Dec 23 | Jefferies | Downgrade | Buy → Hold | — | $14.63 | $15.72 | +7.5% | +17.8% | -1.2% | +7.5% | -4.2% | +20.0% |
| Dec 19 | Piper Sandler | Maintains | Overweight → Overweight | — | $12.25 | $18.68 | +52.5% | +36.8% | -12.7% | +17.8% | -1.2% | +7.5% |
| Jul 23 | Piper Sandler | Upgrade | Neutral → Overweight | — | $7.55 | $8.42 | +11.5% | +9.5% | -3.9% | -6.7% | -0.3% | -8.2% |
| Sep 20 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $2.70 | $2.70 | +0.0% | -3.0% | -3.8% | -1.6% | -1.6% | +0.8% |
| Aug 30 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $2.96 | $2.94 | -0.7% | -3.4% | +12.6% | -7.5% | +0.7% | +0.0% |
| Aug 30 | Jefferies | Upgrade | Hold → Buy | — | $2.96 | $2.94 | -0.7% | -3.4% | +12.6% | -7.5% | +0.7% | +0.0% |
| Aug 6 | Maxim Group | Downgrade | Buy → Hold | — | — | — | — | — | — | — | — | — |
| Aug 3 | William Blair | Downgrade | Outperform → Market Perform | — | $7.98 | $7.98 | +0.0% | +0.0% | -58.9% | -14.0% | -2.8% | -10.2% |
| Aug 3 | Piper Sandler | Downgrade | Overweight → Neutral | — | $7.98 | $7.98 | +0.0% | +0.0% | -58.9% | -14.0% | -2.8% | -10.2% |
| Aug 3 | Chardan Capital | Maintains | Sell → Sell | — | $7.98 | $7.98 | +0.0% | +0.0% | -58.9% | -14.0% | -2.8% | -10.2% |
| May 29 | Chardan Capital | Maintains | Sell → Sell | — | — | — | — | — | — | — | — | — |
| Mar 1 | Chardan Capital | Maintains | Sell → Sell | — | $6.60 | $6.46 | -2.1% | -2.1% | -1.9% | +0.3% | +1.3% | -5.9% |
| Feb 1 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $6.60 | $7.20 | +9.1% | +8.8% | +1.4% | +0.5% | +8.2% | +3.8% |
| Dec 5 | Jefferies | Downgrade | Buy → Hold | — | $7.34 | $7.78 | +6.0% | -1.6% | -5.8% | -6.2% | +0.6% | -2.8% |
| Sep 6 | Piper Sandler | Maintains | Overweight → Overweight | — | $5.86 | $6.08 | +3.8% | -2.0% | -0.7% | +3.5% | +3.1% | +6.9% |
| Jun 2 | Chardan Capital | Maintains | Sell → Sell | — | $6.92 | $6.68 | -3.5% | -1.4% | -2.6% | -7.8% | +0.0% | -3.9% |
| Aug 30 | Chardan Capital | Maintains | Sell → Sell | — | $14.78 | $14.78 | +0.0% | -0.9% | -10.8% | -7.4% | +1.3% | +3.9% |
| Apr 6 | Maxim Group | Upgrade | Hold → Buy | — | $16.52 | $16.80 | +1.7% | +2.3% | +0.1% | +1.2% | -0.6% | -0.7% |
| Jan 18 | Jefferies | Downgrade | Buy → Hold | — | — | — | — | — | — | — | — | — |
| Dec 21 | Maxim Group | Downgrade | Buy → Hold | — | $18.54 | $17.98 | -3.0% | -7.3% | -4.4% | +8.8% | -2.2% | +0.8% |
| Dec 3 | Chardan Capital | Downgrade | Neutral → Sell | — | $31.68 | $31.50 | -0.6% | -0.6% | +2.3% | +2.7% | +1.5% | +1.2% |
| Nov 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.60 | $23.90 | +1.3% | -0.1% | +16.9% | +14.7% | +5.9% | -8.7% |
| Oct 22 | RBC Capital | Maintains | Sector Perform → Perform | — | $22.48 | $22.34 | -0.6% | +0.1% | -0.4% | -2.9% | -1.0% | -3.3% |
| Oct 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.18 | $37.18 | +0.0% | +0.0% | -35.3% | +6.4% | -5.4% | -0.2% |
| May 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.40 | $25.90 | -1.9% | -4.2% | +1.4% | +4.4% | -2.0% | -0.2% |
| Jul 17 | Maxim Group | Maintains | Buy → Buy | — | $12.00 | $12.56 | +4.7% | +12.5% | -3.6% | +0.9% | +0.8% | +7.6% |
| Jun 7 | H.C. Wainwright | Maintains | Buy → Buy | — | $11.24 | $12.04 | +7.1% | +10.0% | -1.6% | +0.7% | -3.4% | -1.2% |
| Mar 21 | Credit Suisse | Downgrade | Neutral → Underperform | — | $12.84 | $12.62 | -1.7% | -4.8% | -0.8% | -6.6% | +5.1% | -1.0% |
| Jun 13 | Credit Suisse | Downgrade | Outperform → Neutral | — | $14.14 | $14.14 | +0.0% | +0.0% | -40.6% | +0.7% | -2.4% | -5.6% |
| Mar 6 | JP Morgan | Downgrade | Overweight → Neutral | — | — | — | — | — | — | — | — | — |
| Feb 19 | Chardan Capital | Maintains | Neutral → Neutral | — | $10.14 | $9.92 | -2.2% | +2.2% | +17.2% | +0.0% | +15.0% | -8.2% |
| Jan 20 | Credit Suisse | Maintains | Outperform → Outperform | — | $10.26 | $10.46 | +1.9% | +0.4% | +1.0% | +7.3% | +1.3% | +0.5% |
| Dec 8 | JP Morgan | Maintains | Overweight → Overweight | — | $12.18 | $12.00 | -1.5% | -5.6% | +1.4% | -4.3% | -6.1% | -8.4% |
No insider trades available.
No recent filings available.
Institutional (13F) — Top 0
All ↗
No 13F holders found.
Mutual Funds / ETFs (N-PORT) — Top 3
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Polen 5Perspectives Small Growth Fund | 11,765 | $203K | Jan 2026 |
| 2 | ActivePassive International Equity ETF | 3,947 | $63K | Feb 2026 |
| 3 | Boston Partners Long/Short Research Fund | -28,324 | $-448935 | Feb 2026 |
Valuation
Market Cap
$1.87B
Enterprise Value
$1.78B
P/E (TTM)
-18.45x
Forward P/E
—
PEG Ratio
2.44x
P/B
3.13x
P/S
108.85x
P/FCF
-36.94x
EV/EBITDA
—
Shares Out
120.8M
Financials (TTM)
Revenue
$17.2M
Net Income
-$102.1M
EBITDA
-$58.2M
Free Cash Flow
-$50.7M
Op Cash Flow
-$50.0M
EPS Basic
$-0.84
EPS Diluted
$-0.84
EPS Forward
$-0.36
Gross Margin
-208.5%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$784.7M
Total Liab.
$187.2M
Total Equity
$597.4M
Cash
$161.2M
LT Debt
$67.7M
Book Value/Sh
$4.95
Debt/Equity
0.21x
Current Ratio
1.99
Quick Ratio
1.77
Returns & Growth
ROE
—
ROA
—
ROIC
-8.5%
Rev Growth YoY
+191.4%
EPS Growth YoY
+5.3%
Price Returns
2W
+2.1%
1M
-1.7%
3M
-2.8%
6M
-10.6%
12M
+44.7%
Technicals
52W High
$20.96
52W Low
$10.16
50d MA
$14.96
200d MA
$16.24
RSI (14)
56.10
ATR (14)
$0.49
Beta
0.82
Avg Volume
170K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$11.50
High
$12.00
Low
$11.00
Median
$11.50
Data updated apr 26, 2026 11:53am
· Source: financialmodelingprep.com